Analyst Activity – SunTrust Banks Lowers Its Price Target On CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT) to

Analyst Ratings For CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT)

Story continues below

Today, SunTrust Banks lowered its price target on CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT) to per share.

Some recent analyst ratings include

  • 4/5/2018-HC Wainwright Reiterated Rating of Buy .
  • 2/8/2018-Roth Capital initiated coverage with a Buy rating.
  • 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
  • 8/3/2017-Stifel Nicolaus Reiterated Rating of Buy.

Recent Insider Trading Activity For CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT)
CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT) has insider ownership of 13.90% and institutional ownership of 39.49%.

  • On 4/8/2015 Daniel L Kisner, Director, bought 4,000 with an average share price of $5.75 per share and the total transaction amounting to $23,000.00.
  • On 7/30/2013 David F Hale, Director, bought 2,588 with an average share price of $11.00 per share and the total transaction amounting to $28,468.00.
  • On 7/30/2013 Luke Evnin, Major Shareholder, bought 165,265 with an average share price of $11.00 per share and the total transaction amounting to $1,817,915.00.
  • On 7/30/2013 Steven J Mento, CEO, bought 13,800 with an average share price of $11.00 per share and the total transaction amounting to $151,800.00.

Recent Trading Activity for CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT)
Shares of CNAT – Conatus Pharmaceuticals closed the previous trading session at 4.37 down -1.64 27.29% with 4.440000057220459 shares trading hands.

An ad to help with our costs